MDS is a bone marrow failure disorder
MDS is a blood cancer
Learn More >
Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator

Developed by the International Working Group for the Prognosis of MDS (IWG-PM) under the aegis of the MDS Foundation, Inc.

When entering values into the calculator, note the units given in parentheses. Also note that the usual ranges, given for orientation, are in brackets. These are not normal ranges.

Variables (units) [usual range]
Hemoglobin (g/dL) [4-20]
A possible conversion for Hb values:
10 g/dL= 6.2 mmol/L, 8 g/dL= 5.0 mmol/L
Absolute Neutrophil Count (x109/L) [0-15]
Platelets (x109/L) [0-2000]
Bone Marrow Blasts (percent) [0-30]
Cytogenetic Category
Very Good  Good  Intermediate  Poor  Very Poor
Age-adjusted calculation of risk (IPSS-RA):
(only for survival estimation)
Age Years
(including age)
(including age)

IPSS-R Cytogenetic risk groups*,**

Cytogenetic prognostic subgroups Cytogenetic abnormalities
Very good -Y, del(11q)
Good Normal, del(5q), del(12p), del(20q), double including del(5q)
Intermediate del(7q), +8, +19, i(17q), any other single or double independent clones
Poor -7, inv(3)/t(3q)/del(3q), double including -7/del(7q), Complex: 3 abnormalities
Very poor Complex: >3 abnormalities

IPSS-R Prognostic Score Values*

Prognostic variable 0 0.5 1 1.5 2 3 4
Cytogenetics Very Good Good Intermediate Poor Very Poor
BM Blast % <=2 >2-<5% 5-10% >10%
Hemoglobin =>10 8-<10 <8
Platelets =>100 50-<100 <50
ANC =>0.8 <0.8

IPSS-R Prognostic Risk Categories/Scores*

Very Low <=1.5
Low >1.5 - 3
Intermediate >3 - 4.5
High >4.5 - 6
Very High >6

IPSS-R: Prognostic Risk Category Clinical Outcomes*

No. pts Very Low Low Intermediate High Very High
Patients (%) 7012 19% 38% 20% 13% 10%
Survival*** 8.8 5.3 3.0 1.6 0.8
AML/25%***,^ NR 10.8 3.2 1.4 0.7


***Medians, years ^Median time to 25% AML evolution
*Greenberg, Tuechler, Schanz et al, Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndrome, Blood 120: 2454, 2012.
**Schanz J et al, J Clin Oncology 2012; 30:820
Review answers to commonly asked questions or get answers to your questions from an MDS expert